



US009278123B2

(12) **United States Patent**
Sauerberg et al.(10) **Patent No.:** **US 9,278,123 B2**
(45) **Date of Patent:** **Mar. 8, 2016**(54) **SOLID COMPOSITIONS COMPRISING A
GLP-1 AGONIST AND A SALT OF
N-(8-(2-HYDROXYBENZOYL)AMINO)
CAPRYLIC ACID**2010/0210526 A1 8/2010 Joshi
2011/0142800 A1 6/2011 Kidron et al.
2011/0218148 A1 9/2011 Azria et al.
2015/0150811 A1 6/2015 Jensen et al.(75) Inventors: **Per Sauerberg**, Farum (DK); **Simon
Bjerregaard**, Hilleroed (DK);
Flemming Seier Nielsen, Roskilde (DK)

FOREIGN PATENT DOCUMENTS

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.CN 101010339 A 8/2007
WO 0048589 A1 8/2000
WO 0050012 A1 8/2000
WO 0141737 A2 6/2001
WO 03005944 A1 1/2003
WO 2005004900 A1 1/2005
WO 2005107773 A2 11/2005
WO 2006/097537 A2 9/2006
WO 2006103661 A2 10/2006
WO 2006124047 A2 11/2006
WO 2007117706 A2 10/2007
WO 2007146234 A2 12/2007
WO 2008020096 A1 2/2008
WO 2008039351 A2 4/2008
WO 2008109385 A2 9/2008
WO 2009032749 A2 3/2009
WO 2009/050738 A2 4/2009
WO 2010/020978 A1 2/2010
WO 2010/092163 A2 8/2010
WO 2011084618 A2 7/2011
WO 2011094531 A1 8/2011
WO 2011109787 A1 9/2011
WO 2011116139 A2 9/2011
WO 2012080471 A1 6/2012(21) Appl. No.: **13/994,262**(22) PCT Filed: **Dec. 16, 2011**(86) PCT No.: **PCT/EP2011/073060**§ 371 (c)(1),
(2), (4) Date: **Sep. 16, 2013**(87) PCT Pub. No.: **WO2012/080471**PCT Pub. Date: **Jun. 21, 2012**(65) **Prior Publication Data**

US 2013/0345134 A1 Dec. 26, 2013

Related U.S. Application Data(60) Provisional application No. 61/425,087, filed on Dec.
20, 2010.(30) **Foreign Application Priority Data**

Dec. 16, 2010 (EP) 10195285

(51) **Int. Cl.****A61K 9/20** (2006.01)**A61K 38/26** (2006.01)**A61P 3/04** (2006.01)**A61P 3/10** (2006.01)(52) **U.S. Cl.**CPC **A61K 38/26** (2013.01); **A61K 9/2013**
(2013.01); **A61K 9/2077** (2013.01)(58) **Field of Classification Search**CPC **A61K 9/20**; **A61K 38/26**; **A61P 3/04**;
A61P 3/10

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,773,647 A 6/1998 Leone-Bay et al.
5,866,536 A 2/1999 Leone-Bay et al.
7,049,283 B2 5/2006 Ault et al.
8,039,018 B2 10/2011 Majuru et al.
8,053,429 B2 11/2011 Cumming et al.
2005/0009748 A1 1/2005 Dinh et al.
2005/0148497 A1 7/2005 Khan
2007/0049557 A1 3/2007 Ahmed et al.
2007/0224262 A1 9/2007 Majuru et al.
2008/0153779 A1 6/2008 Liao et al.
2009/0124639 A1 5/2009 Oyewumi et al.
2009/0156478 A1 * 6/2009 Lau et al. 514/12Beglinger et al., "Pharmacokinetics and pharmacodynamic effects of
oral GLP-1 and PYY3-36: A proof of concept study in healthy sub-
jects," Clin. Pharma. Therap. 84: 468-474 (2008)).*Beglinger C et al., Clinical Pharmacology and
Therapeutics, "Pharmacokinetics and Pharmacodynamic Effects of
Oral GLP-1 and PYY3-36: A Proof-of-Concept Study in Healthy
Subject", 2008, vol. 84, No. 4, pp. 468-474.Steinert RE et al, American Journal of Clinical Nutrition, "Oral
Administration of Glucagon-Like Peptide 1 or Peptide YY 3-36
Affects Food Intake in Healthy Male Subjects", 2010, vol. 92, pp.
810-817.Steinert RE et al., Clinical Pharmacology and Therapeutics, "Orally
Administered Glucagon-like Peptide-1 Affects Glucose Homeostasis
Following an Oral Glucose Tolerance Test in Healthy Male Sub-
jects", 2009, vol. 86, No. 6, pp. 644-650.He Xiaorong et al., Mechanistic Study of the Effect of Roller Com-
paction and Lubricant on Tablet Mechanical Strength, Journal: Jour-
nal of Pharmaceutical Sciences, Year: 2007, vol. 96, No. 5, pp. 1342-
1355.Mollan Jr. Matthew J. et al., The effects of lubrication on the com-
paction and post-compaction properties of directly compressible
maltodextrins, Journal: International Journal of Pharmaceutics, Year:
1996, vol. 144, Issue 1, pp. 1-9.Rowe Raymond C et al., Book: Handbook of Pharmaceutical
Excipients, Title: Acesulfame Potassium, Edition—5th, Year: 2006,
Complete book.Steinert R E et al., Orally Administered Glucagon-Like Peptide-1
Affects Glucose Homeostasis Following an Oral Glucose Tolerance
Test in Healthy Male Subjects, Journal: Clinical Pharmacology and
Therapeutics, Year: 2009, vol. 86, No. 6, pp. 644-650.

(Continued)

Primary Examiner — Julie Ha*Assistant Examiner* — Kristina M Hellman(74) *Attorney, Agent, or Firm* — Richard W. Bork(57) **ABSTRACT**The present invention relates to solid compositions compris-
ing a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)
amino)caprylic acid and their use in medicine.**19 Claims, No Drawings**